-
Subject Areas on Research
-
A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines.
-
A comprehensive outlook on intracerebral therapy of malignant gliomas.
-
A reevaluation of CD22 expression in human lung cancer.
-
Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies.
-
Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.
-
Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
-
Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.
-
Analysis of primate renal allografts after T-cell depletion with anti-CD3-CRM9.
-
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
-
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
-
Antitransferrin receptor immunotoxin inhibits proliferating human retinal pigment epithelial cells.
-
Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer.
-
Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.
-
Clearance of antitransferrin receptor immunotoxin from the rabbit eye.
-
Clinical immunotherapy for brain tumors.
-
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
-
Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.
-
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
-
EGF mutant receptor vIII as a molecular target in cancer therapy.
-
EGFRvIII as a promising target for antibody-based brain tumor therapy.
-
EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.
-
Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.
-
Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.
-
Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide.
-
Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
-
Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.
-
FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts.
-
Graft survival in a rhesus renal transplant model after immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and steroids.
-
Imaging of convection enhanced delivery of toxins in humans.
-
Immune status assay (ISA): a noninvasive procedure for studying allograft rejection.
-
Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
-
Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18.
-
Immunotoxin Therapy for Lung Cancer.
-
Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection.
-
Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome.
-
Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
-
Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.
-
Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
-
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
-
Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.
-
Increased glomerular deposits of von Willebrand factor in chronic, but not acute, rejection of primate renal allografts.
-
Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand.
-
Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.
-
Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
-
Inhibition of human corneal epithelium with immunotoxin 454A12-rRA.
-
Inhibition of human subconjunctival fibroblast proliferation by immunotoxin.
-
Inhibition of proliferating lens epithelium with antitransferrin receptor immunotoxin.
-
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
-
Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.
-
Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes.
-
Mechanisms of tolerance induced by an immunotoxin against CD3 epsilon in a rhesus kidney allograft model.
-
Monensin enhances the cytotoxic effect of antitransferrin receptor immunotoxin on cultured RPE cells.
-
Monoclonal antibodies for brain tumour treatment.
-
Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma.
-
N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies.
-
Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy.
-
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.
-
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
-
Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.
-
Primate renal transplants using immunotoxin.
-
Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
-
Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates.
-
Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.
-
Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.
-
Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
-
Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
-
Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
-
Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.
-
Reversal of acute allograft rejection using immunotoxin.
-
SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.
-
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
-
Split tolerance induced by immunotoxin in a rhesus kidney allograft model.
-
Strategies for tolerance induction in nonhuman primates.
-
Suppression of human corneal epithelial proliferation with breast carcinoma immunotoxin.
-
Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.
-
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
-
The antiproliferative effect of a transferrin-toxin on human retinal pigment epithelial cells and rabbit fibroblasts.
-
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
-
The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody.
-
Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation.
-
Toxin-based targeted therapy for malignant brain tumors.
-
Treatment with immunotoxin.
-
Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells.
-
Keywords of People
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Immunology